These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21057566)

  • 61. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.
    Shelley MD; Kynaston H; Court J; Wilt TJ; Coles B; Burgon K; Mason MD
    BJU Int; 2001 Aug; 88(3):209-16. PubMed ID: 11488731
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
    Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bladder tumors invading the lamina propria (stage T1): influence of endovesical BCG therapy on recurrence and progression.
    Boccon-Gibod L; Leleu C; Herve JM; Belas M; Steg A
    Prog Clin Biol Res; 1989; 310():161-9. PubMed ID: 2771991
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
    Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
    J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy.
    Cookson MS; Sarosdy MF
    J Urol; 1992 Sep; 148(3):797-801. PubMed ID: 1512829
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
    Lambert EH; Pierorazio PM; Olsson CA; Benson MC; McKiernan JM; Poon S
    BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M; Loertzer H; Horsch R; Keller H
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
    Luciani LG; Neulander E; Murphy WM; Wajsman Z
    Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
    Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
    Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Reiter's syndrome postintravesical Bacillus Calmette-Guérin instillations.
    Ng KL; Chua CB
    Asian J Surg; 2017 Apr; 40(2):163-165. PubMed ID: 25183290
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Controversies in the management of T1 urothelial bladder cancer.
    Azzouz H; Cauberg EC; De Reijke TM
    Minerva Urol Nefrol; 2011 Dec; 63(4):309-15. PubMed ID: 21996986
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era.
    Takaoka E; Matsui Y; Inoue T; Miyazaki J; Nakashima M; Kimura T; Oikawa T; Kawai K; Yoshimura K; Habuchi T; Ogawa O; Nishiyama H
    Jpn J Clin Oncol; 2013 Apr; 43(4):404-9. PubMed ID: 23444116
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic impact of ReTURB in high grade T1 primary bladder cancer.
    Sanseverino R; Napodano G; Campitelli A; Addesso M
    Arch Ital Urol Androl; 2016 Jul; 88(2):81-5. PubMed ID: 27377079
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Conservative treatment of high-risk (T1G3) transitional carcinoma].
    Catanzaro F; Torelli F; Catanzaro M; Cappellano F; Pizzoccaro M; Baruffi M; Sironi D; Pozzoli GL
    Arch Ital Urol Androl; 1996 Feb; 68(1):21-4. PubMed ID: 8664915
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT; Soloway MS
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment options for high-risk T1 bladder cancer: status quo and future perspectives of radiochemotherapy.
    Weiss C; Ott OJ; Wittlinger M; Krause SF; Fietkau R; Sauer R; Rödel C
    Strahlenther Onkol; 2008 Sep; 184(9):443-9. PubMed ID: 19016022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.